Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety

NCT05684640
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

NCT00769899
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7325, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

NCT04473664
View directory record Official record
Conditions
Hepatic Impairment, Moderate Impaired Hepatic Function
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 16, 2026, 5:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09

NCT02027155
View directory record Official record
Conditions
Anesthesia
Interventions
AR09 solution, placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

NCT04041648
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 16, 2026, 5:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

NCT06009237
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-903, Placebo for ABBV-903
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects

NCT04951505
View directory record Official record
Conditions
Healthy Subjects
Interventions
cefepime-taniborbactam
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

NCT03933488
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-994, TAK-994 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate BMS-830216 in Healthy Subjects

NCT00878020
View directory record Official record
Conditions
Obesity
Interventions
BMS-830216, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

NCT02858973
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 16, 2026, 5:12 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteer Study

NCT07270783
View directory record Official record
Conditions
Healthy Volunteer
Interventions
D-2570, Placebo
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

NCT00750256
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

NCT04497662
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KPL-404, Matching Placebo
Drug · Other
Lead sponsor
Kiniksa Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

NCT05388903
View directory record Official record
Conditions
Netherton Syndrome
Interventions
DS-2325a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
View directory record Official record
Conditions
Healthy, Drug Drug Interaction
Interventions
Itraconazole, Rifampin, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

NCT06148181
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-141, Placebo for ABBV-141
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

NCT05702983
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions
STSA-1002 subcutaneous injection
Drug
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Industry
Eligibility
21 Years to 57 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

NCT05732194
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-333, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

NCT01473953
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
liraglutide-depot, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

NCT06072157
View directory record Official record
Conditions
Healthy Participants, Chronic Spontaneous Urticaria
Interventions
AK006-IV, Placebo-IV, AK006-SC, Placebo-SC
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 16, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

NCT01975337
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 16, 2026, 5:12 AM EDT